![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, November 12, 2013 5:22:06 PM
(CNN) -- If you're not on medicine to lower your cholesterol yet, you might be soon.
In what's being called a tectonic shift in the way doctors will treat high cholesterol, the American Heart Association and the American College of Cardiology on Tuesday released new treatment guidelines calling for a focus on risk factors rather than just cholesterol levels.
The new guidelines could double the amount of people on medication to lower their cholesterol, experts say.
"This is an enormous shift in policy as it relates to who should be treated for high levels of cholesterol," said Dr. Steven Nissen, chief of cardiovascular medicine at the Cleveland Clinic.
The biggest change from the old guidelines, he says: Ignore the numbers.
Watch this video
Report: More Americans should take statins
Watch this video
Test your cholesterol knowledge
Watch this video
Know your cholesterol numbers
"For many years, the goal was to get the 'bad' cholesterol levels -- or LDL levels -- below 100," Nissen said. "Those targets have been completely eliminated in the new guidelines, and the threshold for treatment has been eliminated."
In their place, the guidelines suggest using specific risk factors to determine who should be treated with cholesterol-lowering statin drugs, and who should simply make lifestyle changes.
Among the four questions to ask to determine risks: Do you have heart disease? Do you have diabetes (Type 1 or 2)? Do you have a bad cholesterol level more than 190? And is your 10-year risk of a heart attack greater than 7.5%?
According to the new guidelines, if you answered yes to any of those four questions, you should be on a statin. Period.
New drugs could drop cholesterol to extreme lows
For those who do not fit those criteria, the committee behind the new policy says lifestyle and behavior management should be sufficient to help manage high cholesterol.
"The focus for years has been on getting the LDL low," said Dr. Neil Stone, committee chairman.
"Our guidelines are not against that. We're simply saying how you get the LDL low is important. Considering all the possible treatments, we recommend a heart-healthy lifestyle and statin therapy for the best chance of reducing your risk of stroke or heart attack in the next 10 years."
Calculating risks
So how do you and your doctor determine if your 10-year risk of a heart attack is above 7.5% and you should be put on a statin?
A simple calculation, said Dr. Donald Lloyd-Jones, chairman of the committee that developed the equation.
"We were able to generate very robust risk equations for both non-Hispanic white men and women as well as African-American men and women," Lloyd-Jones said. "Those equations factor in age, sex, race, total and HDL ('good') cholesterol levels, blood pressure levels, blood pressure treatment status as well as diabetes and current smoking status."
Each of those factors is assigned a numerical value and can be used to determine individual risk percentage using an online calculator.
The hope, Lloyd-Jones said, is that by doing these calculations, patients can be more informed about their risks when going to see doctors.
"The greatest strength behind these guidelines is that they hit at the heart of prevention -- which is that lifestyle, rather than treating isolated risk factors, is the key to reducing risk of chronic disease," said Dr. Sharon Horesh Bergquist, an assistant professor of medicine at Emory University, in an e-mail.
"We tend to focus on 'quick fix' answers such as a pill ... whereas the risk reduction from lifestyle changes, such (as) exercise three-four days a week, reduces risk nearly double to that from any one of the medication interventions."
Double the prescriptions
By changing the way doctors evaluate a patient for statin therapy, Nissen said these new guidelines will effectively double the number of Americans eligible for statin therapy, bringing the total to about 72 million.
How to boost your 'good' cholesterol
So does this mean big bucks for the pharmaceutical companies? Nissen said no -- and in fact, it may mean a downturn in their business.
"Now, except for Crestor, they're virtually all generic -- you can get a three-month supply for $10," he said. "So there's really no money to be made with statins anymore."
He goes on to say that while prescriptions for these drugs will increase dramatically, the guidelines all but shunned other cholesterol-lowering drugs such as Zetia, a big moneymaker for Merck & Co.
Aside from the financial aspects of medicating 35 million more Americans, using statins in a much broader population has been controversial.
Some people, such as cancer expert Dr. David Agus, advocate giving everyone older than 45 a statin, due both to cholesterol-lowering properties and potential benefit in reducing cancer.
Others say that with the potential side effects from statin use -- muscle pains and soreness, a potential moderate increase in liver disease and a risk for developing Type 2 diabetes -- they should be used with care.
Nissen, who strongly disagrees with Agus' suggestion on statins, said a measured approach is best.
"If you have a young woman who is otherwise healthy, giving (her) a statin doesn't make any sense at all," Nissen said. "I do believe the evidence is solid that if you have risk, that statins are enormously beneficial."
Other recommendations
In addition to the guidelines on evaluating cholesterol risk, the American Heart Association and American College of Cardiology released two other sets of guidelines relating to overall heart health.
One report gives guidelines for eating a heart-healthy diet, including reducing saturated and trans fats as well as limiting sodium to 2,400 milligrams per day -- 30% less than the average American consumes on a daily basis.
Cholesterol levels: What numbers should you aim for?
The other report dealt with treatment guidelines for physicians on managing weight loss in their patients. They include a call to create individualized weight loss plans and recommend counseling with a dietitian or other certified weight loss professional for at least six months.
That report also goes on to suggest that doctors should begin offering bariatric surgery as a potentially viable option to improve health for patients with a body mass index over 40, or those with a BMI over 35 and other complicating factors.
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM